| __timestamp | Agios Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 381287000 |
| Thursday, January 1, 2015 | 35992000 | 452612000 |
| Friday, January 1, 2016 | 50714000 | 316800000 |
| Sunday, January 1, 2017 | 71124000 | 330100000 |
| Monday, January 1, 2018 | 114145000 | 265800000 |
| Tuesday, January 1, 2019 | 132034000 | 336200000 |
| Wednesday, January 1, 2020 | 149070000 | 423900000 |
| Friday, January 1, 2021 | 121445000 | 467000000 |
| Saturday, January 1, 2022 | 121673000 | 487000000 |
| Sunday, January 1, 2023 | 119903000 | 477100000 |
| Monday, January 1, 2024 | 156784000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, United Therapeutics Corporation has consistently outpaced Agios Pharmaceuticals, Inc. in SG&A spending. From 2014 to 2023, United Therapeutics' SG&A expenses have grown by approximately 25%, peaking at nearly 487% of Agios' 2023 expenses. This trend highlights United Therapeutics' aggressive investment in administrative and sales functions, potentially fueling its market expansion. Meanwhile, Agios Pharmaceuticals has seen a more modest increase of around 526% in SG&A costs, reflecting a more conservative growth strategy. The data underscores the strategic differences between these two companies, offering insights into their operational priorities and market positioning. As the pharmaceutical sector continues to evolve, monitoring these financial metrics will be key to understanding future industry dynamics.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.